宫颈癌TIGIT表达与临床特征关联性分析  

Cervical cancer TIGIT expression and clinical correlation

作　　者：王永刚 黄莉[1] 范佩文 冯亚宁 王若峥[1] WANG Yong-gang;HUANG Li;FAN Pei-wen;FENG Ya-ning;WANG Ruo-zheng(State Key Laboratory of Pathogenesis,Prevention and Treatment of High Incidence Diseases in Central Asia,Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region,Key Laboratory of Cancer Immunotherapy and Radiotherapy,Chinese Academy of Medical Sciences,Affiliated Tumor Hospital of Xinjiang Medical University,Urumqi 830011,P.R.China)

机构地区：[1]新疆医科大学附属肿瘤医院中国医学科学院肿瘤免疫与放疗研究重点实验室·新疆肿瘤学重点实验室·省部共建中亚高发病成因与防治国家重点实验室,新疆乌鲁木齐830011

出　　处：《中华肿瘤防治杂志》2020年第20期1657-1663,共7页Chinese Journal of Cancer Prevention and Treatment

基　　金：国家自然基金项目(U1603282);中国医学科学院院外重点实验室建设项目(2019PT310021)。

摘　　要：目的通过检测宫颈癌患者外周血及癌组织T细胞中T细胞免疫球蛋白和免疫受体酪氨酸基抑制模体(T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif,TIGIT)的表达,探讨其与宫颈癌患者临床特征的关联性,为宫颈癌免疫治疗的开展提供理论依据。方法收集2017-10-19-2019-06-17新疆医科大学附属肿瘤医院收治的52例宫颈癌初治患者的外周血和癌组织作为病例组,收集2019-09-10-2019-09-30同院健康体检科就诊的18名女性健康志愿者的外周血作为对照组,采用流式细胞术分别检测外周血和癌组织T细胞中TIGIT的表达,比较宫颈癌患者与健康志愿者外周血、宫颈癌患者外周血与癌组织中T细胞TIGIT的表达差异,并分析TIGIT与宫颈癌患者临床特征的关联性。结果宫颈癌患者外周血CD4+T、CD8+T细胞中TIGIT的表达水平分别为(24.10±8.02)%、(50.69±18.32)%,健康志愿者分别为(18.21±4.73)%、(36.00±10.38)%,宫颈癌患者高于健康志愿者,tCD4=-3.740,tCD8=-4.163,均P<0.001。癌组织CD4+T、CD8+T细胞中TIGIT的表达水平分别为(57.90±16.77)%、(73.72±23.44)%,均高于外周血,tCD4=-15.828,tCD8=-6.525,均P<0.001。CD4+T细胞上TIGIT表达在宫颈癌患者外周血与癌组织中呈正相关,rs=0.309,P=0.026。宫颈癌患者外周血CD8+T细胞上TIGIT的表达在不同年龄(T=-2.267,P=0.023)、是否绝经(T=-2.577,P=0.010)、有无流产史(t=-2.274,P=0.027)、有无HPV感染(T=-2.334,P=0.020)中差异有统计学意义。癌组织CD4+T细胞TIGIT的表达在不同年龄(T=-2.827,P=0.005)、是否绝经(t=-2.304,P=0.025)中差异有统计学意义。但在肿瘤大小、分化程度、肿瘤的大体类型、临床分期和淋巴结转移等因素差异无统计学意义,均P>0.05。结论宫颈癌患者外周血中TIGIT的表达高于健康志愿者,但低于癌组织;年龄、月经状况、HPV感染及流产史影响外周血中TIGIT的表达水平。OBJECTIVE TIGIT,T cell immunoreceptor with Ig and ITIM domains,has been studied in many cancers such as non-small cell lung cancer,but few in cervical cancer.The purpose of this study was to explore the relationship between TIGIT and clinical characteristics of patients with cervical cancer by detecting the expression of TIGIT in T cells in peripheral blood and cancer tissues of patients with cervical cancer,so as to provide theoretical basis for immunotherapy of cervical cancer.METHODS The peripheral blood and cancer tissues of 52 patients with cervical cancer treated in the Affiliated Cancer Hospital of Xinjiang Medical University from October 19,2017 to June 17,2019 were collected as the case group.The peripheral blood of 18 healthy volunteers(who were examined in the Affiliated Cancer Hospital of Xinjiang Medical University from September 10,2019 to September 30,2019)were collected as the control group.The expression of TIGIT on T cells in peripheral blood and cancer tissues was detected by flow cytometry.By comparing the difference of TIGIT expression in peripheral blood T cells between cervical cancer patients and healthy volunteers,and the difference of TIGIT expression in cancer tissues and peripheral blood T cells of cervical cancer patients,the relationship between TIGIT and clinical characteristics of cervical cancer patients was analyzed.RESULTS The expression levels of TIGIT in CD4^+T and CD8^+T cells of cervical cancer patients were(24.10±8.02)%and(50.69±18.32)%,respectively.The expression levels of TIGIT in CD4^+T and CD8^+T cells of healthy volunteers were(18.21±4.73)% and(36.00±10.38)%,respectively.The expression levels of TIGIT in CD4^+T and CD8^+T cells from peripheral blood of cervical cancer patients were significantly higher than those of healthy volunteers(tCD4=-3.740,tCD8=-4.163,both P<0.001).The expression levels of TIGIT in CD4^+T cells and CD8^+T cells in cancer tissues were(57.90±16.77)%and(73.72±23.44)%,respectively,which were significantly higher than those in peripheral blood

关 键 词：宫颈癌 T细胞 CD4 CD8 TIGIT 流式细胞技术 

分 类 号：R737.33[医药卫生—肿瘤]